Y-mAbs Therapeutics (YMAB) News Today $4.71 +0.08 (+1.73%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.70 -0.01 (-0.21%) As of 06/13/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock YMAB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $15.60 Consensus PT from BrokeragesJune 12 at 3:00 AM | americanbankingnews.comWe're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn RateJune 11, 2025 | finance.yahoo.comWesbanco Bank Inc. Acquires Shares of 55,000 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Wesbanco Bank Inc. acquired a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 55,000 shares of the company's stock, valued at approximately $244,000. Wesbanco Bank Inc. owned 0.1June 11, 2025 | marketbeat.comCantor Fitzgerald Comments on YMAB FY2026 EarningsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for Y-mAbs Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings of ($1.04) per shareJune 10, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have issued a buy recomJune 9, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DEBank of America Corp DE grew its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 59.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 127,159 shares of the company's stock after acquiring an additiJune 8, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at OppenheimerOppenheimer cut their price objective on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday.May 30, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)Wedbush restated an "outperform" rating and set a $18.00 price objective (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday.May 29, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)Wedbush reaffirmed an "outperform" rating and issued a $18.00 price target (down from $21.00) on shares of Y-mAbs Therapeutics in a research note on Wednesday.May 29, 2025 | marketbeat.comY-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded PipelineMay 28, 2025 | globenewswire.comInfinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Infinitum Asset Management LLC acquired a new position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 155,529 shares of the company's stock,May 28, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025May 26, 2025 | insidermonkey.comY-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingMay 26, 2025 | globenewswire.comY-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdlesMay 24, 2025 | investing.comHC Wainwright Brokers Decrease Earnings Estimates for YMABY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Investment analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns now expects that the company will post earMay 23, 2025 | marketbeat.comFY2026 Earnings Forecast for YMAB Issued By HC WainwrightY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Stock analysts at HC Wainwright issued their FY2026 EPS estimates for shares of Y-mAbs Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.92) per share for the year. HMay 22, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC WainwrightHC Wainwright lowered their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Monday.May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)D. E. Shaw & Co. Inc. reduced its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 21.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 615,131 shares of the company's stock after sMay 20, 2025 | marketbeat.comWedbush Cuts Earnings Estimates for Y-mAbs TherapeuticsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Research analysts at Wedbush decreased their Q2 2025 earnings per share estimates for Y-mAbs Therapeutics in a research report issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($May 17, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have given a buy recommendMay 17, 2025 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)May 16, 2025 | theglobeandmail.comParadigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Paradigm Biocapital Advisors LP raised its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 3.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,236,346 shares of the company's stock after purchasing an additional 150,000 sMay 16, 2025 | marketbeat.comY-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesMay 14, 2025 | finance.yahoo.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | finanznachrichten.deY-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comY-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025May 13, 2025 | globenewswire.comY-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | globenewswire.comY-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)May 7, 2025 | globenewswire.comY-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025May 6, 2025 | globenewswire.comShort Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1%Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 3,070,000 shares, a drop of 16.1% from the March 31st total of 3,660,000 shares. Based on an average daily volume of 400,200 shares, the days-to-cover ratio is presently 7.7 days. Currently, 8.9% of the company's stock are short sold.May 5, 2025 | marketbeat.com2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by Acorn Capital Advisors LLCAcorn Capital Advisors LLC acquired a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 2,861,825 shares of the company's stock, valued at approximately $22May 4, 2025 | marketbeat.comCaligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 47.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,767,982 shares of the company's stocMay 3, 2025 | marketbeat.comRenaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Renaissance Technologies LLC grew its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 371.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 131,600 shares of the company's stock after purchasing an additionMay 3, 2025 | marketbeat.comY-mAbs Therapeutics (YMAB) Projected to Post Earnings on TuesdayY-mAbs Therapeutics (NASDAQ:YMAB) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-y-mabs-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)JPMorgan Chase & Co. boosted its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 221.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 97,660 shares of the company's stoApril 30, 2025 | marketbeat.comBoothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Boothbay Fund Management LLC grew its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 24.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 693,693 shares of the company's stock after purchasing an additionaApril 29, 2025 | marketbeat.comY-mAbs Therapeutics announces presentation of PK data of CD38-SADAApril 28, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measuresApril 27, 2025 | finance.yahoo.comY-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual MeetingApril 27, 2025 | globenewswire.comBrookline Capital Management Weighs in on YMAB Q1 EarningsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities research analysts at Brookline Capital Management lowered their Q1 2025 earnings per share estimates for Y-mAbs Therapeutics in a research note issued to investors on Tuesday, April 22nd. Brookline Capital Management analyst K. DollApril 27, 2025 | marketbeat.comY-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platformApril 26, 2025 | markets.businessinsider.comY-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of AmericaBank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research report on Tuesday.April 24, 2025 | marketbeat.comY-mAbs Therapeutics downgraded to Underperform from Neutral at BofAApril 23, 2025 | markets.businessinsider.comY-mAbs downgraded to Underperform at BofA on tough near-term setupApril 23, 2025 | markets.businessinsider.comY-mAbs drops as Bank of America downgrades on headwinds to DanyelzaApril 23, 2025 | msn.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one hasApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) was the target of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 3,660,000 shares, a decline of 17.6% from the March 15th total of 4,440,000 shares. Approximately 10.6% of the shares of the company are short sold. Based on an average trading volume of 426,500 shares, the days-to-cover ratio is presently 8.6 days.April 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.April 16, 2025 | cnn.comY-mAbs Therapeutics: A Yawn From The Market Means OpportunityApril 11, 2025 | seekingalpha.com Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Media Mentions By Week YMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMAB News Sentiment▼0.990.89▲Average Medical News Sentiment YMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMAB Articles This Week▼104▲YMAB Articles Average Week Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRAX News Today ARDX News Today LENZ News Today OCS News Today ZYME News Today NTLA News Today NUVB News Today AVBP News Today IMNM News Today PHAR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMAB) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy YMAB Stock Free YMAB Stock Alerts